Cardiex Unveils Cardiology Report in CONNEQT App, Enhancing Heart Health Management

CardieX Limited ( (AU:CDX) ) has issued an update.

Cardiex Limited has launched a new Cardiology Report feature in its CONNEQT App, now available on the Apple App Store. This update enhances the app by providing users with a comprehensive cardiovascular health assessment, translating clinically validated biomarkers into an easy-to-understand format. The feature is designed for proactive heart health management, enabling users to track cardiovascular indicators, identify risks, and make informed decisions. It is expected to increase user engagement and lays the groundwork for future monetization opportunities, reinforcing Cardiex’s leadership in digital heart health transformation.

More about CardieX Limited

Cardiex Limited is a company focused on advancing medical technology in vascular health. It offers a suite of products including medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders, leveraging its market-leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange (ASX: CDX).

Technical Sentiment Signal: Sell

Current Market Cap: $23.95M

For a thorough assessment of CDX stock, go to TipRanks’ Stock Analysis page.